Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitors
© 2022 The Authors..
Identification of tumors harboring an overall active immune phenotype may help for selecting patients with advanced head and neck squamous cell carcinomas (HNSCC) and non-small cell lung cancer (NSCLC) who may benefit from immunotherapies. In this context, we generated targeted gene expression profiles in three and two independent cohorts of patients with HNSCC or NSCLC respectively, treated or not by PD-1/PD-L1 inhibitors. Notably, we generated two datasets including 102 and 82 patients with HNSCC or NSCLC treated with PD-1/PD-L1 inhibitors. Clinical information, including detailed survival raw data, is available for each patient, allowing to test association between gene expression data and patient survival (overall and progression-free survival). Moreover, we also generated gene expression datasets of 27 paired HNSCC samples from diagnostic biopsies and versus surgically resected specimens as well as 33 paired HNSCC samples at initial diagnosis (untreated) and at recurrence. Those datasets may allow to test the stability of a given biomarker across paired samples.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Data in brief - 44(2022) vom: 01. Okt., Seite 108556 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Foy, Jean-Philippe [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarker |
|---|
| Anmerkungen: |
Date Revised 17.09.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.dib.2022.108556 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346280370 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346280370 | ||
| 003 | DE-627 | ||
| 005 | 20231226031038.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.dib.2022.108556 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1154.xml |
| 035 | |a (DE-627)NLM346280370 | ||
| 035 | |a (NLM)36111282 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Foy, Jean-Philippe |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitors |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 17.09.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 The Authors. | ||
| 520 | |a Identification of tumors harboring an overall active immune phenotype may help for selecting patients with advanced head and neck squamous cell carcinomas (HNSCC) and non-small cell lung cancer (NSCLC) who may benefit from immunotherapies. In this context, we generated targeted gene expression profiles in three and two independent cohorts of patients with HNSCC or NSCLC respectively, treated or not by PD-1/PD-L1 inhibitors. Notably, we generated two datasets including 102 and 82 patients with HNSCC or NSCLC treated with PD-1/PD-L1 inhibitors. Clinical information, including detailed survival raw data, is available for each patient, allowing to test association between gene expression data and patient survival (overall and progression-free survival). Moreover, we also generated gene expression datasets of 27 paired HNSCC samples from diagnostic biopsies and versus surgically resected specimens as well as 33 paired HNSCC samples at initial diagnosis (untreated) and at recurrence. Those datasets may allow to test the stability of a given biomarker across paired samples | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a Head and neck cancer | |
| 650 | 4 | |a Immunotherapy | |
| 650 | 4 | |a Non-small cell lung cancer | |
| 650 | 4 | |a Transcriptome profile | |
| 700 | 1 | |a Karabajakian, Andy |e verfasserin |4 aut | |
| 700 | 1 | |a Ortiz-Cuaran, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Boussageon, Maxime |e verfasserin |4 aut | |
| 700 | 1 | |a Michon, Lucas |e verfasserin |4 aut | |
| 700 | 1 | |a Bouaoud, Jebrane |e verfasserin |4 aut | |
| 700 | 1 | |a Fekiri, Dorssafe |e verfasserin |4 aut | |
| 700 | 1 | |a Robert, Marie |e verfasserin |4 aut | |
| 700 | 1 | |a Baffert, Kim-Arthur |e verfasserin |4 aut | |
| 700 | 1 | |a Hervé, Geneviève |e verfasserin |4 aut | |
| 700 | 1 | |a Quilhot, Pauline |e verfasserin |4 aut | |
| 700 | 1 | |a Attignon, Valéry |e verfasserin |4 aut | |
| 700 | 1 | |a Girod, Angélique |e verfasserin |4 aut | |
| 700 | 1 | |a Chaine, André |e verfasserin |4 aut | |
| 700 | 1 | |a Benassarou, Mourad |e verfasserin |4 aut | |
| 700 | 1 | |a Zrounba, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Caux, Christophe |e verfasserin |4 aut | |
| 700 | 1 | |a Ghiringhelli, François |e verfasserin |4 aut | |
| 700 | 1 | |a Lantuejoul, Sylvie |e verfasserin |4 aut | |
| 700 | 1 | |a Crozes, Carole |e verfasserin |4 aut | |
| 700 | 1 | |a Brochériou, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Pérol, Maurice |e verfasserin |4 aut | |
| 700 | 1 | |a Fayette, Jérôme |e verfasserin |4 aut | |
| 700 | 1 | |a Bertolus, Chloé |e verfasserin |4 aut | |
| 700 | 1 | |a Saintigny, Pierre |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Data in brief |d 2014 |g 44(2022) vom: 01. Okt., Seite 108556 |w (DE-627)NLM251298183 |x 2352-3409 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2022 |g day:01 |g month:10 |g pages:108556 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.dib.2022.108556 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2022 |b 01 |c 10 |h 108556 | ||